HOME >> MEDICINE >> NEWS
Research questions transplant safety procedure

Lyophilization, a method once thought to inactivate retroviruses such as HIV from bones and connective tissues used in transplant procedures, may not be quite as effective as originally thought, researchers at Michigan State University have concluded.

In a paper to be presented at an upcoming meeting of the American Orthopaedic Society for Sports Medicine, MSU scientists said their research shows the method, known as lyophilization or freeze-drying, does not improve the safety of bones and tissues for transplantation, something that could affect thousands of transplant recipients.

"We were able to demonstrate that this type of tissue processing does not inactivate systemically infected tendon and bone tissues," said Steven P. Arnoczky, the Wade O. Brinker Endowed Professor of Surgery in MSU's College of Veterinary Medicine and one of the lead researchers in the project. "Contrary to currently held clinical beliefs, lyophilization should not be relied upon as an extra measure of security for processing connective tissue allografts."

Bones, ligaments and other tissues that will be used for orthopedic transplants frequently are treated with gamma irradiation or a chemical "cocktail" in an effort to remove any bacteria or viruses which may have evaded the rigorous donor-screening process.

However, these methods can create additional problems, as they sometimes change the tissue's biological and biomechanical properties.

A clinical study published in 1985 suggested that lyophilization may inactivate HIV. Therefore, many surgeons who were seeking an extra measure of protection for their patients would specifically request tissues that had gone through the lyophilization process.

"This has completely changed a long-held belief," Arnoczky said, "and it's a very important contribution, as it got rid of the false sense of security people had with that process."

In their experiment,
'"/>

Contact: Tom Oswald
oswald@msu.edu
517-355-2281
Michigan State University
31-Mar-2004


Page: 1 2

Related medicine news :

1. Researchers search for first sign of congestive heart failure
2. Research offers hope of new treatments for liver damage
3. Research suggests possible blood test for multiple sclerosis
4. Researchers say breast cancer in Africa may provide clues to the disease in African-Americans
5. 2005 Award for Basic Research in Biological Mineralization
6. 2005 Craniofacial Biology Research Award
7. 2005 Research in Dental Caries Award
8. 2005 Research in Prosthodontics and Implants Award
9. 2005 Basic Research in Periodontal Disease Award
10. 2005 Research in Oral Biology Award
11. 2005 Pulp Biology Research Award

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Research questions transplant safety procedure

(Date:4/24/2014)... from The University of Manchester have identified a way ... more open to treatment. , The study published today ... for the development of drugs to target cells that ... made the discovery whilst exploring the possible mechanisms behind ... treat breast and colon cancer. , Dr Andrew Gilmore, ...
(Date:4/24/2014)... with an antimicrobial peptide could help to lower the risk ... Optometry and Vision Science , official journal of the ... published by Lippincott Williams & Wilkins , a part ... and now humans support the biocompatibility and safety of lenses ... research by Debarun Dutta, B.Optom, of The University of New ...
(Date:4/24/2014)... new Institute for Biomedical Sciences at Georgia State ... grant to develop novel therapeutics against Respiratory Syncytial ... Eunice Kennedy Shriver National Institute Of Child Health ... Health will support Plemper,s drug development goals of ... distinct alternative compound. , Infections by RSV, a ...
(Date:4/24/2014)... than one out of three survivors of critical ... The Lancet Respiratory Medicine , and the ... than mentally. , It is one of the ... functional outcomes of critical care survivors, according to ... Medicine, and it highlights a significant public health ...
(Date:4/24/2014)... has found a relationship between motor skill deficiencies and ... in very young children. , The findings, believed ... relationship between motor skills and autism severity, indicate that ... included in treatment plans for young children with autism, ... of Public Health and Human Sciences. , "Recognizing ...
Breaking Medicine News(10 mins):Health News:Scientists find way to target cells resistant to chemo 2Health News:Study supports safety of antimicrobial peptide-coated contact lenses 2Health News:Study supports safety of antimicrobial peptide-coated contact lenses 3Health News:Vanderbilt study finds physical signs of depression common among ICU survivors 2Health News:Vanderbilt study finds physical signs of depression common among ICU survivors 3Health News:Motor skill deficiencies linked to autism severity in new research 2
(Date:1/15/2014)...  Echo Therapeutics, Inc. (Nasdaq: ECTE ) ("Echo"), ... as a non-invasive, wireless continuous glucose monitoring system, today ... and Interim CEO of Echo Therapeutics, will present at ... Mr. Doman will make a corporate ...
(Date:1/15/2014)... , Jan. 15, 2014 Reportlinker.com ... is available in its catalogue: ... Drug Forecast and Market Analysis to 2022 ... PharmaPoint: Atopic Dermatitis - India Drug Forecast ...
(Date:1/15/2014)... 15, 2014  Zafgen, Inc., a leading biopharmaceutical company ... obese patients, today announced initial results from its ... of methionine aminopeptidase 2 (MetAP2), in patients with ... obesity.  These results showed improvements in body weight, ...
Breaking Medicine Technology:Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4
Cached News: